Drug intelligence / Profile preview

Melocin

Development stage: Discontinued
Lead developer: Morepen Laboratories
Modality: Small Molecules
Administration: Oral

Overview

**Melocin** is a brand name for a 400 mg tablet formulation of a fluoroquinolone antibiotic used to treat bacterial infections, including those of the urinary tract, nose, and throat. It belongs to the quinolone class of antibiotics that inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and leading to bacterial cell death. Developed and marketed by companies such as Dr. Morepen Ltd. and Global Pharma, it is prescribed for susceptible bacterial infections but carries risks of tendon rupture, QT prolongation, and Clostridium difficile-associated diarrhea.[8][9][11]

Brand names: Melocin

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on Melocin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melocin.

Explore the full profile